No Data
No Data
Jim Cramer Says You Should Buy Johnson & Johnson (JNJ), Thinks Talc Problems 'Behind It'
J&J Posts Mid-stage Trial Data for Chemotherapy Releasing System in Bladder Cancer
Johnson & Johnson's TAR-200 Monotherapy Achieves High Disease-free Survival of More Than 80 Percent in BCG-unresponsive, High-risk Papillary NMIBC
Express News | Johnson & Johnson - Initiates FDA Application for Tar-200 Under Rtor Program
Express News | Johnson & Johnson - Phase 2B Study: 82% Achieve Complete Response, 52.9% Cancer-Free at One Year
Express News | Johnson & Johnson's Tar-200 Monotherapy Demonstrates Highest Complete Response Rate With Sustained Clinical Benefits in Patients With Certain Types of Bladder Cancer
loading...